Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Subsidiary Submits NDA For Alzheimer's Disease Drug In Japan

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo subsidiary Asubio Pharma submitted an NDA for SUN Y7017 (memantine) for Alzheimer's disease in Japan. An N-methyl-D-aspartate receptor antagonist developed by German firm Merz Pharmaceuticals, memantine was approved by the European Medicines Agency in 2002 and by U.S. FDA in 2003.The drug is now marketed in over 60 countries. Developed by Asubio in Japan, memantine will be marketed by Daiichi Sankyo upon approval. (Click here for more - Japanese language

You may also be interested in...



UK Waives Import Taxes On COVID-19 Products

Suppliers to the UK’s National Health Service from outside the EU could save up to 12% during COVID-19 emergency measures as the UK tries to increase supplies

Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts. 

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

UsernamePublicRestriction

Register

SC073985

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel